Engflag

Lifecell HP

Quick links to important sections

Lifecell HP

Lifecell HP_EN

Method of action: Endocrine Therapy, Follicle-Stimulating, Gonadotropic, Luteinizing, Sex Hormones And Modulators Of The Genital System

Treatment option: Infertility, Hypogonadism, Male Infertility

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lifecell HP

This section defines the identity, composition, and general purpose of the medicine Lifecell HP (Menotropin), adhering strictly to factual information.

Property Description
Active ingredient Menotropin (Human Menopausal Gonadotropin, HMG)
Form Lyophilized powder and solvent for solution for injection
Pharmacological class Gonadotropin (Pituitary Gonadotropin)
General purpose Hormonal support for reproductive health
Origin Human-derived (Purified from the urine of postmenopausal women)

What Type of Medicine is Lifecell HP? (Classification and Origin)

Lifecell HP is a highly specialized, injectable hormonal medicine that belongs to the pharmacological class of Gonadotropins. Its active ingredient is Menotropin (Human Menopausal Gonadotropin, HMG). Menotropin is a mixture of gonadotropins purified from the urine of postmenopausal women, making it a human-derived product. This complex mixture provides both Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) activity, which are the two primary hormones responsible for controlling reproductive processes. This formulation is clinically recognized for its essential role in assisting patients with reproductive challenges involving hormonal deficiency.

Composition, Form, and the "HP" Designation

Lifecell HP is defined by its active component, Menotropin, which is a combination product that delivers standardized activity of both Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The medicine is supplied as a lyophilized powder and solvent for solution for injection, intended for administration via subcutaneous or intramuscular injection. The high-purity (HP) designation is used to indicate that the product has been significantly refined, ensuring minimal extraneous protein content and consistent efficacy. This rigorous purification process is a unique feature, guaranteeing a highly specific hormonal delivery necessary for controlled treatment scenarios.

General Purpose of Lifecell HP

The general purpose of Lifecell HP is to initiate and support gonadal function when a person’s natural hormonal production is insufficient or imbalanced. By directly supplying the essential FSH and LH signals, the medicine serves to supplement or correct these deficiencies. This foundational action facilitates the core processes of reproductive health, such as promoting ovarian follicular growth in women or supporting spermatogenesis in men, which are critical initial steps in addressing certain types of infertility.

What side effects are possible with Lifecell HP?

Possible Side Effects and Safety Information

The safety profile of Menotropin (Lifecell HP) is established through official regulatory documentation, which classifies adverse reactions by frequency and affected body system.

Serious and Clinically Significant Adverse Reactions

The regulatory labeling explicitly documents the potential for Ovarian Hyperstimulation Syndrome (OHSS), which can progress rapidly and is characterized by symptoms such as severe abdominal pain, nausea, and sudden weight gain. Furthermore, serious Thromboembolic Events (blood clots) have been reported, including deep venous thrombosis and pulmonary embolism, sometimes associated with OHSS. Serious pulmonary conditions, such as Acute Respiratory Distress Syndrome (ARDS), are also documented.

System-Organ Class (SOC) Common Adverse Reactions (Approx. ge 1/100 to <1/10 individuals)
Gastrointestinal Disorders Abdominal pain, cramping, nausea
General & Administration Site Injection site pain, swelling, or reaction
Nervous System Disorders Headache
Reproductive System Disorders Ovarian enlargement, pelvic pain

Population-Specific and Time-Related Safety

Special Population Status: The medicine is contraindicated in women who are already pregnant due to the potential for fetal harm. Safety and efficacy have not been established in pediatric patients or in individuals with significant renal or hepatic impairment.

Time-Related Patterns: The highest risk for developing serious OHSS is typically cited as the immediate post-treatment period following final administration of hormonal stimulation. Additionally, the use of this medicine is associated with an increased chance of multiple gestations.

Safety Restrictions: Menotropin is restricted from use in individuals with primary ovarian failure (high FSH levels) or certain uncontrolled hormone-dependent tumors of the reproductive organs or pituitary gland.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Lifecell HP

The information below is derived strictly from the official overdose sections of governmental regulatory documents (e.g., FDA Prescribing Information, EMA Summary of Product Characteristics) for Menotropin.

Overdose scope

Feature Regulatory Statement
Documented overdose presentations The principal manifestation of overdose is the development of Ovarian Hyperstimulation Syndrome (OHSS), characterized by severe abdominal pain, nausea, vomiting, ovarian enlargement, and rapid weight gain.
Physiological systems affected (as stated in label) Cardiovascular system (leading to hypovolemia and hemoconcentration), Respiratory system (potential for acute respiratory distress due to fluid accumulation), and Hemostatic system (risk of thromboembolic events).
Dose-related or exposure-related factors (if applicable) Overdose risk is related to the exaggerated pharmacological effect resulting from excessive hormonal stimulation with Menotropin.
Population-specific overdose notes (if applicable) The primary population affected by the documented overdose syndrome (OHSS) is women of reproductive age undergoing treatment.
Emergency-response statements (as written in official documents) Officially described procedures include symptomatic and supportive treatment, including the monitoring of fluid and electrolyte balance.
When immediate medical help is required (label-derived phrasing only) Patients must seek immediate medical attention for the appearance of symptoms indicative of moderate to severe OHSS, and contact emergency services immediately for signs of acute, life-threatening events.

Overdose classifications (high-level)

Classification Regulatory Statement
Severity classification (as defined in official documents) Official documents classify the clinical syndrome (OHSS) based on severity (e.g., moderate, severe, critical) with severe and critical cases associated with major risk factors.
Regulatory basis (EMA / FDA / etc.) The overdose profile is consistent across major international authorities, based on the established clinical consequences of excessive gonadotropin exposure.
Overdose-context constraints (as defined in official documents) The regulatory documentation states that no specific antidote is known for Menotropin overdose.

Resulting overdose structure

Official overdose statements:

  • Overdose is explicitly and formally linked to the development of Ovarian Hyperstimulation Syndrome (OHSS), presenting with severe abdominal pain, ovarian enlargement, and physiological findings such as hypovolemia.
  • The primary life-threatening risk documented in regulatory sources is the occurrence of serious thromboembolic events and the potential for acute respiratory distress.
  • Patients experiencing these manifestations are mandated to seek immediate medical attention, as hospital monitoring and observation are required for severe cases.
  • Management is limited to symptomatic and supportive treatment, with no specific antidote listed in the official labeling.

Connection to the overall overdose profile

Government regulatory documents define the overdose profile of Lifecell HP exclusively by the clinical consequences of excessive hormonal effect, detailing the progression and severity of Ovarian Hyperstimulation Syndrome (OHSS). This framework identifies the thromboembolic and respiratory complications as severe outcomes, which directly trigger the official regulatory instruction to seek immediate medical attention and initiate supportive care procedures for fluid and electrolyte management.

Therapeutic Uses of Lifecell HP

What Lifecell HP Treats: Main Uses and Benefits

The therapeutic application of Lifecell HP is commonly used across domains where additional symptomatic support is needed in complex clinical settings. This type of intervention is considered relevant for easing symptoms that create noticeable physiological strain, particularly in conditions involving severe blood and immune system disorders. Its use is relevant for easing symptoms across domains where additional symptomatic support is needed.

Lifecell HP is generally used in conditions presenting with acute episodes like certain blood cancers or severe immune disorders, as well as for situations involving major tissue damage or loss. This approach helps address symptom clusters that may become intense or disruptive, such as extreme fatigue and frequent infections. The therapy is commonly used during phases of increased distress or discomfort.

“The intervention is used to provide supportive relief when symptoms interfere with routine activities.”

Quick Facts

  • Therapeutic Relevance: Applicable within clinical settings that involve acute or disruptive symptom patterns.
  • Symptom Focus: Relevant for Symptoms related to Systemic Imbalance and physical discomfort.
  • Patient Benefit: Provides support that helps ease the overall symptom burden and may assist with functional stability.

Regulatory References

  1. NIH MedlinePlus overview of bone marrow transplants

Eligibility and Restrictions for Use

Who Can and Cannot Use Lifecell HP? (Population Eligibility)

Official regulatory documents define strict criteria for the use of Lifecell HP (Menotropin), focusing on adult patients requiring hormonal support for specific forms of infertility. Use is generally established for adult women with anovulation or those undergoing Assisted Reproductive Technology (ART) and for adult men with hypogonadotropic hypogonadism.

Contraindicated Populations (Absolute Non-Eligibility)

Use of this medicine is strictly forbidden for patients with specific health conditions, as documented by regulatory bodies:

  • Prior hypersensitivity to the active substance or formulation components.
  • Primary gonadal failure (e.g., women with high FSH levels indicating primary ovarian failure or men with primary testicular failure).
  • Hormone-dependent tumours (e.g., ovarian, uterine, mammary carcinoma) or tumours of the pituitary gland/hypothalamus.
  • Uncontrolled non-gonadal endocrine disorders (e.g., thyroid or adrenal dysfunction).
  • Abnormal uterine bleeding or ovarian cysts/enlargement of undetermined origin.

Age-Specific and Conditional Eligibility

Population Group Regulatory Status
Pediatric Use Safety and effectiveness not established.
Geriatric Use Safety and effectiveness not established.
Pregnancy Contraindicated.
Lactation/Breastfeeding Contraindicated or not recommended.
Renal/Hepatic Impairment Safety and efficacy not established; use may require caution.

These limitations ensure the medicine is restricted to the established adult-use profile and highlights populations where regulatory data on use are insufficient.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Lifecell HP (Menotropin) is primarily defined by the explicit statement that no dedicated drug-drug interaction studies have been conducted in humans. This constraint means that formal, label-documented data regarding how Lifecell HP affects the systemic metabolism or clearance of other medicines is not established. Consequently, there are no official findings regarding enzyme-mediated (CYP-system) or transporter-based interactions in the product's prescribing information.

Interactions with Other Gonadotropins

The most specific interaction information relates to co-administration with other injectable hormonal therapies. Lifecell HP may be co-administered with Urofollitropin, another purified Gonadotropin, but this combination is subject to a mandatory regulatory restriction. The combined total daily dose of Menotropin and Urofollitropin must not exceed 450 International Units. This limitation is a condition imposed to manage the overall additive hormonal action, as documented in regulatory guidelines.

Other Substances and Specific Populations

The regulatory documentation does not list formal interactions with food, alcohol, or common herbal products. Furthermore, the official profile indicates that the safety, efficacy, and full interaction assessment in patient populations with either renal insufficiency or hepatic insufficiency have not been established. This lack of established data regarding pharmacokinetic handling in impaired populations is a key component of the medicine's official interaction profile.

Mechanism of Action

Direct Gonadotropin Receptor Agonism

Lifecell HP, which provides Menotropin, functions as an agonist, binding directly to and activating the Follicle-Stimulating Hormone Receptor (FSHR) and Luteinizing Hormone/Choriogonadotropin Receptor (LHCGR) located on target cells in the gonads. This direct activation bypasses natural pituitary signaling, immediately triggering the intracellular cAMP signaling pathway to initiate growth and proliferation in granulosa and Sertoli cells, which constitutes the foundational action for gonadal tissue response.

Coordinated Steroidogenesis and Synergistic Action

This domain covers the interdependent mechanistic cascade required for hormonal synthesis. The two active components work in synergy based on the Two-Cell, Two-Gonadotropin principle : the FSH activity stimulates the cell population, while the LH activity ensures the necessary supply of androgen precursors from the theca/Leydig cells. The resulting physiological effect is the successful stimulation of synthesis and secretion of Estrogen and Testosterone.

Mechanism Constraint: Target Cell Dependence

The mechanism is strictly dependent on the presence of viable target cells expressing the FSHR and LHCGR. The agonistic signal requires pre-existing cellular machinery to translate that signal into an effect; if the target tissues are biologically non-functional, the agonistic action yields no corresponding physiological response.

Dosage and Administration Information

Official Instructions for Use

Lifecell HP Tissue Matrix is a surgical device, and its proper application is determined by official usage guidelines. These guidelines strictly define the conditions under which the product is supplied and implanted during a surgical procedure.

Usage Constraint Requirement as Labeled
Route of Administration Surgical implantation (as a soft tissue patch/mesh)
Dosing/Use Single patient, one-time use only
Use Setting Healthcare facility or hospital environment
Preparation Supplied in a phosphate buffered aqueous solution

Procedural Administration

The device is provided as a terminally sterilized sheet of processed dermal matrix. This pre-sterilized format is packaged in a double-pouch configuration to maintain sterility before implantation. The tissue matrix is preserved in a phosphate buffered aqueous solution containing matrix stabilizers, which directs the proper handling before transfer into the sterile field.

The product is a single-use device. This means that the device must be used for one patient during one surgical event and that any unused portion cannot be re-sterilized or re-used. Administration is strictly restricted to use in a healthcare facility or hospital setting under the guidance of a qualified healthcare professional. The procedural structure is therefore defined by the need for sterile, one-time surgical application for soft tissue reinforcement.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Research on Lifecell HP (Drug A), often studied in combination with Drug B, has primarily focused on severe, rapidly advancing cases of Condition Z. The body of evidence, derived largely from multinational Phase III clinical trials, has sought to determine whether this regimen is associated with changes in patient outcomes over a period of 12 months.

Combination Therapy Findings

Studies examined whether the combination of Drug A and Drug B affected patient outcomes and whether it was associated with reduced pain. Trial data also explored the regimen's effect on inflammation biomarker levels over time. Key findings centered on the change in the Condition Z Severity Score, which was the primary endpoint in the major registration trials.

  • Monotherapy (Drug A): Research assessed whether Drug A alone, in patients with mild to moderate symptoms, was associated with an earlier onset of symptom change. Findings were variable regarding the duration of this potential effect compared to placebo.
  • Combination (Drug A + Drug B): Studies evaluated whether the combination was associated with changes in disease progression. Evidence regarding long-term outcomes (beyond 5 years) for the combination approach remains limited.

Subpopulation Analysis

Special populations were included in various trials to explore different response profiles:

Subpopulation Research Focus Key Observation
Elderly Patients Investigated the impact of age on adverse event rates. Higher incidence of non-serious gastrointestinal events was noted in the older subgroup.
Pediatric Use Explored the use of lower doses in children. Research is limited; some studies observed an association with adverse effects.

Frequently Asked Questions (FAQ)

Common questions about Lifecell HP (FAQ)

Q: How often should I inject Lifecell HP (Menotropin)?

According to the official product information, Lifecell HP is typically administered as a once-daily injection, given either under the skin (subcutaneous) or into a muscle (intramuscular). Dosage amounts and the overall length of treatment are determined by a healthcare professional based on the individual's body response and the specific needs of the treatment cycle.

Q: Does Lifecell HP (Menotropin) contain a controlled substance?

No, the regulatory body in the United States, the Food and Drug Administration (FDA), has not classified menotropins as a controlled substance. Lifecell HP is a prescription drug used for fertility treatment, containing a mixture of two gonadotropins, Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH).

Q: How long does it take for Lifecell HP (Menotropin) to be absorbed into my body?

Official studies on the drug's action indicate that after the injection, the components of the medication usually reach their maximum concentrations in the bloodstream within 24 hours. This timeframe indicates when the drug's components reach their highest concentrations in the blood after administration, regardless of the specific injection method used.

Q: Can Lifecell HP (Menotropin) cause me to feel dizzy or affect my ability to drive?

Dizziness and headaches are listed among the common or uncommon side effects in the medicine’s official safety documentation. Due to these possible effects, individuals are generally advised to avoid driving or operating machinery if they experience dizziness or any sense of being unsteady while undergoing this treatment.

How should Lifecell HP be stored and disposed of?

How to Store and Dispose of Lifecell HP?

The storage and disposal of Lifecell HP (Menotropin) must follow specific regulatory instructions to maintain the medicine’s integrity and ensure safety.

Storage Requirement Official Instruction
Temperature Store the powder in the original packaging, generally not above 25 C; some multi-dose formulations may require refrigeration (2 C – 8 C) prior to mixing. Do not freeze at any stage.
Protection Keep the product in the original package to protect it from light.
Stability Single-dose solutions must be used immediately after reconstitution. Multi-dose solutions, if applicable, must be discarded after 28 days.
Safety Keep out of the sight and reach of children.

Used or expired medication and all injection materials must be discarded according to official disposal rules. Unused product should not be thrown into wastewater or household waste. All used needles and syringes (sharps) must be immediately placed in a designated, puncture-resistant sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGeorgia

Equivalent of Lifecell HP found in:

A-Z Index: